Fig. 1
From: A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases
A diagram of hRNase5/ANG as an EGFR ligand and a serum biomarker for prediction of erlotinib sensitivity in pancreatic cancer. Secretory hRNase5/ANG acting as an EGFR ligand associates with extracellular domain of EGFR, which in turn induces EGFR dimerization and phosphorylation/activation (red stars), leading to tumorigenesis and increased sensitivity to erlotinib treatment in pancreatic cancer patients. In addition, hRNase5/ANG also competes with other EGFR ligands, such as EGF, for EGFR binding, due to the partially overlapped epitope of EGFR binding region between hRNase5/ANG and EGF. The scale of the diagram does not reflect the relative sizes of different molecules